A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.

Background: Management strategies and clinical outcomes vary substantially in patients newly diagnosed with Crohn's disease. We evaluated the use of a putative prognostic biomarker to guide therapy by assessing outcomes in patients randomised to either top-down (ie, early combined immunosuppression with infliximab and immunomodulator) or accelerated step-up (conventional) treatment strategies.

Methods: PROFILE (PRedicting Outcomes For Crohn's disease using a moLecular biomarker) was a multicentre, open-label, biomarker-stratified, randomised controlled trial that enrolled adults with newly diagnosed active Crohn's disease (Harvey-Bradshaw Index ≥7, either elevated C-reactive protein or faecal calprotectin or both, and endoscopic evidence of active inflammation).

Active surveillance of adverse events following COVID-19 vaccines in a tertiary care hospital.

Background: Vaccination is a safe and effective way to prevent disease and save lives, but it may also produce some undesirable adverse events (AEs)which may affect healthy individuals. Therefore, the monitoring of AE following immunization (AEFIs) is necessary. The objective of this study was to assess the AEs following COVID-19 vaccinations in a tertiary care hospital.

Automatic severity grade classification of diabetic retinopathy using deformable ladder Bi attention U-net and deep adaptive CNN.

Long-term exposure to diabetes mellitus leads to the formation of diabetic retinopathy (DR), which can cause vision loss in working-age adults. Early stage diagnosis of DR is highly essential for preventing vision loss and preserving vision in people with diabetes. The motivation behind the severity grade classification of DR is to develop an automated system that can assist ophthalmologists and healthcare professionals in the diagnosis and management of DR.